Results from a recent international randomized phase II trial for the drug tasquinimod (TASQ), shows that TASQ is a potential therapy for men with advanced prostate cancer. The men who received TASQ on average went twice as long without disease progression as those who received only a placebo. […]
Researchers at the The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland studied the relationship between the change of PSA doubling time (PSADT) and disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. They retrospectively analyzed the data from 96 men diagnosed with biochemically relapsed prostate cancer (BRPC) who [...]
In 2005 there was a small clinical trial performed at UCLA evaluating pomegranate juice and its ability to control PSA for men with prostate cancer. The trial gave 8 oz. of POM Wonderful pomegranate juice each day in men with a rising PSA post treatment (recurrent advanced prostate cancer). This trial, which was funded by [...]
As of now, Congress and the Administration are at an impasse on FY 11 spending. If no deal is reached by Friday, government operations will shut down. This would impact cancer research and prevention programs in the following ways: * Patient enrollment in clinical trials would be discontinued; * No new grants would be awarded; [...]
On March 10th (my birthday) Dendreon announced that it has obtained clearance of its new work stations from the FDA. The result of this clearance is the quadrupling the output from the New Jersey factory where it makes sipuleucel-T (Provenge). When Dendreon obtained FDA clearance in April of 2010, it had extremely limited manufacturing capabilities [...]